Security
Fate Therapeutics, Inc. Common Stock · FATE
FATENASDAQCommon stockCurrentCIK 1434316Updated Nov 14, 2026
FATE price & chart
Loading TradingView…
NASDAQ:FATE on TradingView ↗About the company
Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be administered in combination with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications.
In the news
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences ↗
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them ↗
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment News provided by USA News Group Aug 14, 2025, 12:22 ET Share this article Share to X Share this article Share to X USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Aug. 14, 2025 /PRNew ↗
Recent filings
EFFECT filing
424B5 filing
SCHEDULE 13D/A - filed by Redmile Group, LLC regarding FATE THERAPEUTICS INC
S-3 filing
424B5 filing
Show 5 more recent filings
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement
Items 1.01, 1.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
S-8 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 343,671,000Source | 494,970,000Source | 260,103,000Source | 371,632,000Source | 528,817,000Source | 284,916,000Source | 398,670,000Source | 569,892,000Source | 318,937,000Source | 440,694,000Source | 506,217,000Source | 705,561,000Source |
| Property, Plant and Equipment, NetUSD | 59,475,000Source | 82,392,000Source | 51,546,000Source | 61,097,000Source | 87,534,000Source | 54,262,000Source | 62,762,000Source | 92,116,000Source | 56,925,000Source | 64,384,000Source | 96,836,000Source | 110,020,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 40,622,000Source | 37,909,000Source | 32,429,000Source | 41,249,000Source | 36,917,000Source | 39,570,000Source | 44,920,000Source | 121,322,000Source | 46,628,000Source | 36,056,000Source | 41,870,000Source | 61,333,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 682,000Source | 4,127,000Source | 703,000Source | 1,395,000Source | 1,048,000Source | 704,000Source | 2,406,000Source | 858,000Source | 916,000Source | 3,539,000Source | 1,826,000Source | 38,480,000Source |
| Assets, CurrentUSD | 221,251,000Source | 310,294,000Source | 157,953,000Source | 230,397,000Source | 319,388,000Source | 179,526,000Source | 248,217,000Source | 394,375,000Source | 208,704,000Source | 291,909,000Source | 331,540,000Source | 502,074,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,146,000Source | 9,244,000Source | 3,480,000Source | 6,172,000Source | 13,461,000Source | 4,000,000Source | 5,386,000Source | 9,973,000Source | 4,131,000Source | 9,302,000Source | 14,539,000Source | 27,367,000Source |
| Operating Lease, Right-of-Use AssetUSD | 42,413,000Source | 58,441,000Source | 40,554,000Source | 43,814,000Source | 59,547,000Source | 41,078,000Source | 45,178,000Source | 60,620,000Source | 41,609,000Source | 46,508,000Source | 61,675,000Source | 66,069,000Source |
| Other Assets, NoncurrentUSD | 0Source | 9,000Source | — | 0Source | 9,000Source | — | 0Source | 9,000Source | 0Source | 9,000Source | 9,000Source | 33,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source | 3,000Source |
| Common Stock, Value, IssuedUSD | 115,000Source | 114,000Source | 117,000Source | 115,000Source | 114,000Source | 116,000Source | 115,000Source | 114,000Source | 115,000Source | 114,000Source | 99,000Source | 97,000Source |
| Additional Paid in CapitalUSD | 1,735,730,000Source | 1,707,215,000Source | 1,749,116,000Source | 1,730,869,000Source | 1,695,450,000Source | 1,745,187,000Source | 1,723,715,000Source | 1,685,928,000Source | 1,741,259,000Source | 1,716,335,000Source | 1,580,032,000Source | 1,536,497,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,501,935,000Source | -1,345,841,000Source | -1,595,681,000Source | -1,469,685,000Source | -1,298,163,000Source | -1,565,522,000Source | -1,435,615,000Source | -1,259,736,000Source | -1,534,309,000Source | -1,397,994,000Source | -1,211,732,000Source | -1,050,804,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 153,000Source | 835,000Source | -117,000Source | 62,000Source | -422,000Source | -77,000Source | 191,000Source | -194,000Source | 116,000Source | 268,000Source | 15,000Source | -1,854,000Source |
| Stockholders' Equity Attributable to ParentUSD | 234,066,000Source | 362,326,000Source | 153,438,000Source | 261,364,000Source | 396,982,000Source | 179,707,000Source | 288,409,000Source | 426,115,000Source | 207,184,000Source | 318,726,000Source | 368,417,000Source | 483,939,000Source |
| Liabilities and EquityUSD | 343,671,000Source | 494,970,000Source | 260,103,000Source | 371,632,000Source | 528,817,000Source | 284,916,000Source | 398,670,000Source | 569,892,000Source | 318,937,000Source | 440,694,000Source | 506,217,000Source | 705,561,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 28,111,000Source | 37,422,000Source | 32,592,000Source | 28,673,000Source | 34,793,000Source | 30,689,000Source | 28,159,000Source | 45,369,000Source | 36,071,000Source | 38,522,000Source | 39,094,000Source | 114,051,000Source |
| Operating Lease, Liability, CurrentUSD | 4,751,000Source | 6,893,000Source | 4,922,000Source | 5,656,000Source | 6,644,000Source | 4,740,000Source | 6,544,000Source | 6,402,000Source | 4,562,000Source | 7,416,000Source | 6,176,000Source | 5,628,000Source |
| Accounts Payable, CurrentUSD | 3,504,000Source | 6,349,000Source | 3,258,000Source | 4,040,000Source | 5,495,000Source | 3,277,000Source | 4,190,000Source | 6,765,000Source | 2,656,000Source | 9,365,000Source | 4,719,000Source | 8,265,000Source |
| Operating Lease, Liability, NoncurrentUSD | 74,494,000Source | 92,085,000Source | 70,753,000Source | 75,675,000Source | 93,918,000Source | 72,045,000Source | 76,785,000Source | 95,668,000Source | 73,287,000Source | 77,849,000Source | 97,360,000Source | 103,710,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 17,571,000Source | 23,580,000Source | 14,904,000Source | 18,182,000Source | 22,654,000Source | 13,642,000Source | 17,213,000Source | 32,043,000Source | 20,024,000Source | 21,348,000Source | 27,514,000Source | 53,932,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 387,974,000Source | 362,084,000Source | 323,962,000Source | 296,247,000Source |
| Short-term InvestmentsUSD | 174,801,000Source | 259,014,000Source | 121,341,000Source | 181,581,000Source | 267,962,000Source | 135,252,000Source | 195,505,000Source | — | 157,029,000Source | 243,012,000Source | 273,305,000Source | 374,894,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -31,213,000Source | -37,621,000Source | -136,315,000Source | -186,262,000Source | -160,928,000Source | -281,721,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 2,918,000Source | 3,333,000Source | 12,901,000Source | 18,962,000Source | 18,282,000Source | 13,758,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -212,000Source | -1,134,000Source | -2,624,000Source | 1,113,000Source | -36,654,000Source | 29,804,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | -23,400,000Source | — | -30,822,000Source | -33,809,000Source | -106,084,000Source | -122,874,000Source | -132,263,000Source | -248,208,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 23,587,000Source | 42,673,000Source | 111,166,000Source | 12,218,000Source | 112,665,000Source | 166,751,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 239,000Source | 1,196,000Source | 5,953,000Source | 730,000Source | 6,153,000Source | 35,566,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 5,490,000Source | 99,892,000Source | 85,000Source | 9,207,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -7,235,000Source | 8,864,000Source | 10,572,000Source | -10,764,000Source | -19,513,000Source | -72,250,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 1,600Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,861,000Source | 11,765,000Source | 3,518,000Source | 7,154,000Source | 3,929,000Source | 7,381,000Source | 24,924,000Source | 41,496,000Source | 43,459,000Source | 78,733,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -9,000Source | -942,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 10,638,000Source | 20,801,000Source | 8,829,000Source | 11,445,000Source | 9,596,000Source | 13,773,000Source | 46,521,000Source | 74,169,000Source | 81,448,000Source | 84,232,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,000Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 2,575,000Source | 4,438,000Source | 1,555,000Source | 2,921,000Source | 1,867,000Source | 3,336,000Source | 11,052,000Source | 17,288,000Source | 17,186,000Source | 5,842,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -32,250,000Source | -47,678,000Source | -30,159,000Source | -34,070,000Source | -31,213,000Source | -37,621,000Source | -136,315,000Source | -186,262,000Source | -160,928,000Source | -281,721,000Source |
| Operating ExpensesUSD | — | — | 36,476,000Source | 55,451,000Source | 33,216,000Source | 38,875,000Source | 34,299,000Source | 42,909,000Source | 154,350,000Source | 223,907,000Source | 254,044,000Source | 404,686,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,485,000Source | 4,699,000Source | 975,000Source | 2,898,000Source | 1,787,000Source | 3,659,000Source | 11,389,000Source | 24,014,000Source | 29,583,000Source | 26,665,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 28,729,000Source | 48,624,000Source | 195,143,000Source | 317,750,000Source | 358,810,000Source | 404,796,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 0Source | 295,000Source | 85,000Source | 9,207,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,741,000Source | 3,074,000Source | 2,082,000Source | 1,907,000Source | 1,299,000Source | 1,629,000Source | 6,646,000Source | 13,631,000Source | 63,533,000Source | 96,300,000Source |
| Operating Income (Loss)USD | — | — | -34,735,000Source | -52,377,000Source | -31,134,000Source | -36,968,000Source | -33,000,000Source | -41,280,000Source | -147,704,000Source | -210,276,000Source | -190,511,000Source | -308,386,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,485,000Source | 4,699,000Source | 975,000Source | 2,898,000Source | 1,787,000Source | 3,659,000Source | 11,389,000Source | 24,014,000Source | 29,583,000Source | 26,665,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -32,250,000Source | -47,678,000Source | -30,159,000Source | -34,070,000Source | -31,213,000Source | -37,621,000Source | -136,315,000Source | -186,262,000Source | -160,928,000Source | -281,721,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.27Source | -0.4Source | -0.25Source | -0.29Source | -0.26Source | -0.32Source | -1.15Source | -1.64Source | -1.64Source | -2.91Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.27Source | -0.4Source | -0.25Source | -0.29Source | -0.26Source | -0.32Source | -1.15Source | -1.64Source | -1.64Source | -2.91Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 118,998,693Source | 117,769,161Source | 120,397,390Source | 118,528,046Source | 120,030,638Source | 118,375,540Source | 118,789,974Source | 113,685,177Source | 98,411,162Source | 96,826,058Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 118,998,693Source | 117,769,161Source | 120,397,390Source | 118,528,046Source | 120,030,638Source | 118,375,540Source | 118,789,974Source | 113,685,177Source | 98,411,162Source | 96,826,058Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 10,638,000Source | 20,801,000Source | 8,829,000Source | 11,445,000Source | 9,596,000Source | 13,773,000Source | 46,521,000Source | 74,169,000Source | 81,448,000Source | 84,232,000Source |
| Investment Income, InterestUSD | — | — | 2,575,000Source | 4,438,000Source | 1,555,000Source | 2,921,000Source | 1,867,000Source | 3,336,000Source | 11,052,000Source | 17,288,000Source | 17,186,000Source | 5,842,000Source |
| Operating ExpensesUSD | — | — | 36,476,000Source | 55,451,000Source | 33,216,000Source | 38,875,000Source | 34,299,000Source | 42,909,000Source | 154,350,000Source | 223,907,000Source | 254,044,000Source | 404,686,000Source |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,000,000Source | — |
| Research and Development ExpenseUSD | — | — | 25,838,000Source | 34,650,000Source | 24,387,000Source | 27,430,000Source | 24,703,000Source | 29,136,000Source | 107,829,000Source | 135,001,000Source | 172,596,000Source | 320,454,000Source |
Offerings
Registration 333-299862
Filing attachments
fate-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN Preliminary Phase 1 clinical data presented at ASN Kidney Week 2026 demonstrated 100% renal response in the bendamustine conditioning regimen selected for RECLAIM-LN $15.0 milli…
Read attachment ↗fate-ex99_1.htm · 8-K · 2026-09-28
Exhibit 99.1 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to fund advancing clinical trials for stem cell and gene therapies that have the potential to provide transformative benefits to patients and t…
Read attachment ↗fate-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 fate-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge FDA clearance of the FT839 IND application advances the Company’s novel dual CD19/CD38 targeting off-the-shelf CAR T-cell product…
Read attachment ↗d83385dex991.htm · 8-K · 2026-06-04
EX-99.1 2 d83385dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies Accessible to AllTM CORPORATE PRESENTATION June 2026 | NASDAQ: FATE | Non-Confidential © 2026 Fate Therapeutics. All rights reserved Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety …
Read attachment ↗fate-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 fate-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates RECLAIM - LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026 FDA selects FT819 into the CDRP (CMC Development and Readiness Pilot) program enabling early and enhanced communication with t…
Read attachment ↗fate-ex4_4.htm · 10-K · 2026-02-26
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of this Annual Report on Form 10-K of which this exhibit forms a part, Fate Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock (as defined below). DESCRIPTION OF CAPITAL STOCK The following description of our Common Sto…
Read attachment ↗